NSCLC合并李法美尼综合征患者体细胞驱动基因改变高发
该回顾性研究分析22例携带胚系TP53变异(李法美尼综合征)的NSCLC患者的临床与分子特征,发现90%(19/21)肿瘤存在体细胞驱动基因突变,主要为EGFR突变(18例),另见1例ROS1融合;14例接受EGFR抑制剂治疗者中位总生存37.3个月,7例耐药,其中5例(71%)获得EGFR-T790M突变。
要点
- LFS相关NSCLC多为女性、非吸烟、腺癌、晚期,体细胞驱动突变率高达90%。
- EGFR突变占驱动改变绝大多数,以exon 19缺失最多,亦见ROS1融合。
- EGFR抑制剂治疗中位OS 37.3个月,耐药者71%出现T790M。
核心结论
- LFS相关NSCLC肿瘤中体细胞驱动基因改变发生率为90%,主要为EGFR突变,另见ROS1融合。
研究设计与样本
- 回顾性研究,纳入22例NSCLC合并胚系TP53变异(LFS)患者,共23个肺部肿瘤,分析临床与分子特征。
主要发现
- 22例中女性64%,中位年龄51岁,非吸烟者84%,腺癌73%,晚期84%。
- 患者携带16种不同胚系TP53变异,最常见为p.R158H(5/22,其中3例同一家族)。
- 个人癌症史71%,家族癌症史90%。
- 21个可分析肿瘤中19个(90%)检出体细胞驱动突变:EGFR突变18例(exon 19缺失12例、L858R 3例、G719A、exon 20插入、缺失突变亚型各1例),ROS1融合1例。
- 3例EGFR exon 19缺失肿瘤同时检出PIK3CA突变(3/12)。
临床怎么用
- 对LFS相关NSCLC患者应进行体细胞驱动基因检测,以识别可靶向的EGFR突变等改变。
- EGFR突变阳性者可考虑EGFR抑制剂治疗,耐药后需评估T790M等机制。
局限性
- 回顾性研究,样本量小(22例患者、23个肿瘤、21个肿瘤可分析)。
- 胚系TP53变异与肺癌致癌过程的关系需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Actionable somatic molecular alterations are found in 15% to 20% of NSCLC in Europe. NSCLC is a tumor observed in patients with germline TP53 variants causing Li-Fraumeni syndrome (LFS), but its somatic molecular profile is unknown. METHODS: Retrospective study of clinical and molecular profiles of patients with NSCLC and germline TP53 variants. RESULTS: Among 22 patients with NSCLC and LFS (n = 23 lung tumors), 64% were women, median age was 51 years, 84% were nonsmokers, 73% had adenocarcinoma histological subtype, and 84% were diagnosed with advanced-stage disease. These patients harbored 16 distinct germline TP53 variants; the most common was p.R158H (5/22; three in the same family). Personal and family histories of cancer were reported in 71% and 90% of patients, respectively. In most cases (87%, 13/15), lung cancer was diagnosed with a late onset. Of the 21 tumors analyzed, somatic oncogenic driver mutations were found in 19 of 21 (90%), EGFR mutations in 18 (exon 19 deletion in 12 cases, L858R in three cases, and G719A, exon 20 insertion, and missing mutation subtype, each with one case), and ROS1 fusion in one case. A PI3KCA mutation was concurrently detected at diagnosis in three EGFR exon 19-deleted tumors (3/12). The median overall survival was 37.3 months in 14 patients treated with EGFR inhibitors; seven developed resistance, five (71%) acquired EGFR-T790M mutation, and one had SCLC transformation. CONCLUSIONS: Driver oncogenic alterations were observed in 90% of the LFS tumors, mainly EGFR mutations; one ROS1 fusion was also observed. The germline TP53 variants and lung cancer carcinogenesis driven by oncogenic processes need further evaluation.
引用
- Mezquita L, Jové M, Nadal E, et al. High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome. J Thorac Oncol. 2020. PMID: 32179180. doi:10.1016/j.jtho.2020.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。